G1 Therapeutics, Inc.
GTHXNASDAQHealthcare
$7.16
+$0.01(+0.14%)
Market Cap$377748712
P/E Ratio—
52W High$7.19
52W Low$1.08
G1 Therapeutics, Inc. (GTHX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GTHX · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2024Report Date: Aug 8, 2024EPS Actual
-$0.10
Est. -$0.17 · +41.2%
Revenue
$0.02B
Est. $0.02B · +1.1%
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Aug 8, 2024
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
GTHX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q3 FY2024 | Aug 8, 2024 | -$0.17 | -$0.10 | +41.2% | $0.02B | $0.02B | +1.1% |
| ▼ Q2 FY2024 | May 1, 2024 | -$0.19 | -$0.20 | -5.3% | $0.01B | $0.02B | -5.1% |
| ▲ Q1 FY2024 | Feb 28, 2024 | -$0.27 | -$0.21 | +22.2% | $0.01B | $0.01B | +13.7% |
| ▼ Q4 FY2023 | Nov 1, 2023 | -$0.31 | -$0.35 | -12.9% | $0.01B | $0.01B | -5.9% |
| ▲ Q3 FY2023 | Aug 2, 2023 | -$0.22 | $0.14 | +163.6% | $0.04B | $0.03B | +46.7% |
| ▲ Q2 FY2023 | May 3, 2023 | -$0.64 | -$0.53 | +17.2% | $0.01B | $0.01B | +15.7% |
| ▲ Q1 FY2023 | Mar 1, 2023 | -$0.85 | -$0.73 | +14.1% | $0.01B | $0.01B | +6.1% |
| ▲ Q4 FY2022 | Nov 2, 2022 | -$0.64 | -$0.59 | +7.8% | $0.02B | $0.02B | +1.1% |
Q3 FY2024
Aug 8, 2024Beat
EPS Actual
-$0.10
EPS Est.
-$0.17
EPS Surpr.
+41.2%
Revenue
$0.02B
Q2 FY2024
May 1, 2024Miss
EPS Actual
-$0.20
EPS Est.
-$0.19
EPS Surpr.
-5.3%
Revenue
$0.01B
Q1 FY2024
Feb 28, 2024Beat
EPS Actual
-$0.21
EPS Est.
-$0.27
EPS Surpr.
+22.2%
Revenue
$0.01B
Q4 FY2023
Nov 1, 2023Miss
EPS Actual
-$0.35
EPS Est.
-$0.31
EPS Surpr.
-12.9%
Revenue
$0.01B
Q3 FY2023
Aug 2, 2023Beat
EPS Actual
$0.14
EPS Est.
-$0.22
EPS Surpr.
+163.6%
Revenue
$0.04B
Q2 FY2023
May 3, 2023Beat
EPS Actual
-$0.53
EPS Est.
-$0.64
EPS Surpr.
+17.2%
Revenue
$0.01B
Q1 FY2023
Mar 1, 2023Beat
EPS Actual
-$0.73
EPS Est.
-$0.85
EPS Surpr.
+14.1%
Revenue
$0.01B
Q4 FY2022
Nov 2, 2022Beat
EPS Actual
-$0.59
EPS Est.
-$0.64
EPS Surpr.
+7.8%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.11 | $0.11 | $0.11 | 1 |
| Q3 FY2027 | $0.10 | $0.10 | $0.10 | 1 |
| Q2 FY2027 | $0.08 | $0.08 | $0.08 | 1 |
| Q1 FY2027 | $0.07 | $0.07 | $0.07 | 1 |
| Q4 FY2026 | $0.05 | $0.05 | $0.05 | 1 |
| Q3 FY2026 | $0.03 | $0.03 | $0.03 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2024 | Aug 8, 2024 | +41.2% | $7.06 | $7.09 | +0.42% |
| ▼ Q2 FY2024 | May 1, 2024 | -5.3% | $3.77 | $4.13 | +9.55% |
| ▲ Q1 FY2024 | Feb 28, 2024 | +22.2% | $2.40 | $3.33 | +38.75% |
| ▼ Q4 FY2023 | Nov 1, 2023 | -12.9% | $1.65 | $1.34 | -18.79% |
| ▲ Q3 FY2023 | Aug 2, 2023 | +163.6% | $2.19 | $2.14 | -2.28% |
| ▲ Q2 FY2023 | May 3, 2023 | +17.2% | $2.97 | $3.02 | +1.68% |
| ▲ Q1 FY2023 | Mar 1, 2023 | +14.1% | $3.62 | $3.67 | +1.38% |
| ▲ Q4 FY2022 | Nov 2, 2022 | +7.8% | $10.91 | $8.21 | -24.75% |
Q3 FY2024+0.42%
Report Date
Aug 8, 2024
EPS Beat/Miss
+41.2%
Price Before
$7.06
Price After
$7.09
Q2 FY2024+9.55%
Report Date
May 1, 2024
EPS Beat/Miss
-5.3%
Price Before
$3.77
Price After
$4.13
Q1 FY2024+38.75%
Report Date
Feb 28, 2024
EPS Beat/Miss
+22.2%
Price Before
$2.40
Price After
$3.33
Q4 FY2023-18.79%
Report Date
Nov 1, 2023
EPS Beat/Miss
-12.9%
Price Before
$1.65
Price After
$1.34
Q3 FY2023-2.28%
Report Date
Aug 2, 2023
EPS Beat/Miss
+163.6%
Price Before
$2.19
Price After
$2.14
Q2 FY2023+1.68%
Report Date
May 3, 2023
EPS Beat/Miss
+17.2%
Price Before
$2.97
Price After
$3.02
Q1 FY2023+1.38%
Report Date
Mar 1, 2023
EPS Beat/Miss
+14.1%
Price Before
$3.62
Price After
$3.67
Q4 FY2022-24.75%
Report Date
Nov 2, 2022
EPS Beat/Miss
+7.8%
Price Before
$10.91
Price After
$8.21
Avg Beat Reaction+2.53%
Avg Miss Reaction-4.62%
Beat Rate6 / 8 quarters
Largest Move+38.75% (Q1 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GTHX ends December
G1 Therapeutics, Inc. (GTHX) most recently reported earnings on August 8, 2024 for Q3 FY2024, posting EPS of $-0.10 — beating the analyst consensus of $-0.17 by +41.2%. The next GTHX earnings date is expected around September 1, 2026.
Each quarter, investors track GTHX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GTHX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GTHX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GTHX earnings · 5 questionsG1 Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. GTHX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GTHX historically reports after market close (AMC).
GTHX earnings datewhen is GTHX earningsGTHX next earnings datewhen does GTHX report earningsGTHX earnings calendar
▸ Source: FMP · G1 Therapeutics, Inc. SEC filings · US GAAP · G1 Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026